| P344 | Spherical Nucleic Acid (SNA) TLR9 agonists induce long-term tumor-specific immune responses in synergy with PD-1 checkpoint inhibition | Bart R. Anderson, PhD; SubbaRao Nallagatla, PhD; Richard Kang, PhD; Ekambar R. Kandimalla, PhD | Checkpoint blockade; Immune adjuvant; Solid tumors; TLR |
| P345 | Depletion of plasma arginine with pegzilarginase enhances the anti-tumor activity of immune checkpoint inhibitors | Mark D. Badeaux, PhD; Giulia Agnello, PhD; Danlee Enzler, BS; Leslie Priddy, B.S; Jason F. Wiggins, BS; Christopher Daige; Scott W. Rowlinson, PhD; | Checkpoint blockade; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P346 | A phase 1b/2 study of the safety and efficacy of HBI-8000-nivolumab combination in melanoma (MEL), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) | Nikhil I. Khushalani, MD; Zeynep Eroglu, MD; Andrew S. Brohl, MD; Thai H. Ho, MD, PhD; Heather Yeckes-Rodin, MD; Michael R. Kurman, MD; Reid P. Bissonnette; Mireille Gillings, PhD; Gloria Lee, MD, PhD; | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Tumor evasion; Tumor microenvironment |
| P347 | Targeting phosphatidylserine enhances the anti-tumor response to radiation therapy and immune checkpoint blockade in a preclinical melanoma model | Sadna Budhu, PhD; Rachel A. Giese, MD; Aditi Gupta, BA; Sara Schad, BS; Olivier De Henau, MD; Roberta Zappasodi, PhD; Luis F. Campesato, PhD; Christopher A. Barker, MD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD | Checkpoint blockade; Radiotherapy |
| P348 | Survival and immune modulation in homologous recombination deficient murine ovarian tumors using the PARP inhibitor, rucaparib and immune agonist, NKTR-214 | Deborah Charych, PhD; Liliane Robillard, Ph.D.; Andrew Simmons, PhD; Thomas C. Harding, Ph.D.; Minh Nguyen; Rachel Dusek, PhD; | Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P349 | Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model | Phyllis F. Cheung, PhD; Jens T. Siveke; Anna Bazarna; Christian Neander; Konstantinos Savvatakis; Sven-Thorsten Liffers; Marija Trajkovic-Arsic; Aayush Gupta; Alexander Herner | Coinhibition; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | First-line nivolumab plus ipilimumab is associated with lower costs per responder versus sunitinib among patients with advanced renal cell carcinoma | Toni K. Choueiri; Keith A. Betts, PhD; Shuo Yang, PhD; Ella X. Du, MESc; Sumati Rao, PhD; Saby George, MD, FACP | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P351 | ADU-S100 (MIW815) synergizes with checkpoint inhibition to elicit an anti-tumor CD8+ T cell response to control distal tumors | Kelsey Sivick Gauthier, PhD; Anthony L. Desbien, PhD; Gabrielle Reiner; Leticia Corrales; Weiwen Deng; Laura H. Glickman, PhD; Natalie H. Surh; Brian Francica; David Kanne; Justin J. Leong, PhD; Ken Metchette; Lianxing Zheng; Charles Cho; Yan Feng; Jeffrey M. McKenna; Steve Bender, PhD; Chudi Ndubaku; Meredith L. Leong; Thomas W. Dubensky, Jr.; Andrea van Elsas; Sarah McWhirter; | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P352 | Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the anti-tumor efficacy of immune checkpoint blockade | Colm R. Duffy, B.A.; Stephen Mok; James P. Allison, PhD; | Checkpoint blockade; Chemokine; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P353 | Strategic combination of multiple immune-oncology agents to engage, expand, and enable immune responses against tumors | Kellsye Fabian, PhD; Michelle Padget; Anthony Malamas; Rika Fujii; John Lee, MD; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA | Checkpoint blockade; Chemotherapy; Immune adjuvant; Solid tumors; Vaccine |
| P354 | Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer | Pierre-Olivier Gaudreau; David H. Peng, Ph.D.; Bertha Leticia Rodriguez; Jared J. Fradette; Laura A. Gibson; Samrat Kundu, Ph.D.; Limo Chen, PhD; Jennifer A. Wargo, MD, MMSc; Don L. Gibbons, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P355 | Nivolumab plus ipilimumab is associated with lower number needed to treat compared with sunitinib for preventing death in advanced renal cell carcinoma | Saby George, MD, FACP; Keith A. Betts, PhD; Shuo Yang, PhD; Ella X. Du, MESc; Jennifer Johansen, PharmD, BCPS; Sumati Rao, PhD; Toni K. Choueiri; | Checkpoint blockade; Clinical study; Clinical trial; Targeted therapy |
| P356 | CXCR4 antagonism converts the cold tumor into hot tumor by enhancing the infiltration of antigen-specific CD8 T-cells in the TME leading to increased anti-tumor effects of anti-OX40 | Pankaj Gaur, PhD; Vivek Verma; Rahul Nandre, PhD; Ella Sorani, PhD; Abi Vainstein-Haras, MD; Galia Oberkovitz; Amnon Peled, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; Stephen M. Shaw, PhD; Osnat Bohana-Kashtan; | Costimulation; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P357 | Entinostat increases the frequency of tumor-specific effector T-cells and their functionality is enhanced by anti-OX40 leading to durable anti-tumor effects | Rahul Nandre, PhD; Vivek Verma; Pankaj Gaur, PhD; Hua Wang; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; Samir N. Khleif, MD; | Costimulation; Immune monitoring; T cell; Tumor microenvironment; Vaccine |
| P358 | ROR-gamma agonist induces long-lived Th17 cells in the TME leading to increased anti-tumor effects of agonist anti-OX40 | Pankaj Gaur, PhD; Vivek Verma; Rahul Nandre, PhD; Laura L. Carter, PhD; Xiao Hu, PhD; Xikui Liu, PhD; Seema Gupta, PhD; Samir N. Khleif, MD | Costimulation; Immune monitoring; Tumor microenvironment; Vaccine |
| P359 | Immune cell responses and dose scheduling optimization of radiation and anti-PD-L1 treatment combination using a joint experimental and systems modeling approach | Yuri Kosinsky, PhD; Simon J. Dovedi, PhD; Kirill Peskov, PhD; Veronika Voronova, MSc; Lulu Chu, PhD; Donald R. Stanski, MD; Gabriel Helmlinger, PhD; | Checkpoint blockade; Immune suppression; Radiotherapy; T cell; Tumor microenvironment |
| P360 | Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody | Qun Jiang, PhD; Daniel Rathkey; Jingli Zhang; Ira H. Pastan, MD; Raffit Hassan, MD | Checkpoint blockade; T cell; Targeted therapy |
| P361 | Phase 1/2 study of mogamulizumab (anti-CCR4), to deplete regulatory T-cells, in combination with PD-1 checkpoint inhibitor nivolumab in subjects with locally advanced or metastatic solid tumors | David Hong, MD; Olivier Rixe, MD, PhD; Vi K. Chiu, MD, PhD; Patrick Forde, MD; Tomislav Dragovich, MD; Yanyan Lou, MD; Asha Nayak, MD; Rom Leidner, MD; James Atkins, MD; Agron Collaku, PhD; Floyd E. Fox, PhD; Margaret A. Marshall, MD; Anthony J. Olszanski, MD, RPh; | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy |
| P362 | TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, enhances the anti-tumor effect of radiation and targeted therapy in ovarian cancer models | Lisa Johnson, PhD; Lei LC. Cui, PhD, BS; Hui Chen, BS; April Lewtak, MSc; Sean Oh; Carole Galligan, PhD; Simone Helke; Julia Berchadsky, PhD; Bob Uger, BS, PhD | Checkpoint blockade; Monocyte/Macrophage; Radiotherapy; Solid tumors |
| P363 | Pegzilarginase in combination with agonist anti-OX40 therapy enhances T cell priming and effector function leading to improved tumor regression and survival | Melissa J. Kasiewicz, BS; Annah S. Rolig, Ph. D; Elizabeth R. Sturgill, PhD; Mark D. Badeaux, PhD; Scott W. Rowlinson, PhD; William L. Redmond, PhD | Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P364 | Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214 | Saul Kivimae, PhD; Marlene Hennessy, BS; Rhoneil Pena; Yolanda Kirksey, MSc; Wildaliz Nieves, PhD; Phi Quach, BS PhD; Janet Cetz, BS; Zhongxu Ren, PhD; Haiying Cai, BS; BoLiang Deng, PhD; Wen Zhang, PhD; Fiore Cattaruzza; Christie Fanton, PhD; Neel K. Anand, PhD; Werner Rubas, PhD; Stephen K. Doberstein, PhD; Loui Madakamutil; Jonathan Zalevsky, PhD | Antigen presenting cells; Costimulation; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P365 | Triple checkpoint blockade targeting PD-1, TIM-3, and LAG3 improves T cell reinvigoration and antitumor efficacy over single and double combinations | Johanna K. Kaufmann, PhD; Geeta Sharma; Srimoyee Ghosh, PhD; Sujatha Kumar, PhD; Kevin G. Coleman, PhD; Sridhar Ramaswamy, MD; David Jenkins, PhD | Checkpoint blockade; Coinhibition |
| P366 | Blockade of the PD-1/PD-L1 pathway with the Anti-PD-1 mAb, MGA012, enhances the biological activity of the B7-H3 x CD3 bispecific DART® molecule, MGD009 | Liqin Liu, PhD; Yinhua Yang; Ralph F. Alderson, PhD; Jonathan Li, PhD; Qihong Xu; Daorong Liu; Robert Burns; Vatana Long; Syd Johnson, PhD; Ezio Bonvini; Paul Moore, PhD; | Antibody; Checkpoint blockade; T cell; Tumor antigens |
| P367 | Synergistic anti-tumor effects of TLR4 agonist G100 and anti-OX40 antibody | Hailing Lu, MD, PhD; Alec Betancur; Howard JR. Lee; Jan H. Ter Meulen, MD, PhD | Antigen presenting cells; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P368 | Combination of a dipeptidyl peptidase inhibitor BXCL701 and biased CD122 agonist NKTR-214 with anti-PD1 provides functional immunological memory through inflammatory cell death. | John MacDougall, PhD; Snigdha Gupta, PhD; Veena Agarwal; Luca Rastelli; Annie An; wenqing yang, PhD; Henry Li; Deborah Charych, PhD; Jonathan Zalevsky, PhD; Vincent O'Neill; | Checkpoint blockade; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P369 | Pegilodecakin, a pegylated human IL-10 (AM0010), enhances the cytotoxicity of CAR-T cells In Vitro | Scott McCauley, BA; Rakesh Verma, PhD; Martin Oft, MD; | Adoptive immunotherapy; CAR T cells; Cytokine; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P370 | Forced expression of OX40L and inhibition of IDO within the murine glioblastoma microenvironment creates a potent anti-tumor immune response. | Teresa Nguyen, BS; Yisel A. Rivera-Molina, PhD; Francisco Puerta-Martinez, PhD; Debora Kim; Xuejun Fan, BS; Frederick Lang, MD; Hong Jiang, PhD; Candelaria Gomez-Manzano, MD; Juan Fueyo | Costimulation; Immune suppression; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P371 | Reprogramming the immune phenotype of Rb-deficient tumor cells using BET inhibition | Brian M. Olson, PhD; Christina J. Hong; Riyue Bao, PhD; Gregory B. Lesinski, PhD, MPH; Akash Patnaik, MD, PhD | Biomarkers; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P372 | BETAMUNE, a replication competent type 5 adenovirus carrying a TGF-Beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model | Christopher Larson, MD PhD; Corey A. Carter, MD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; | Antibody; Antigen presenting cells; Checkpoint blockade; Gene expression; Immune suppression; Monocyte/Macrophage; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P373 | Synergistic efficacy of duvelisib with checkpoint or co-stimulatory antibodies in a B cell lymphoma model: Advantages of dual inhibition of PI3K-delta and PI3K-gamma | Jonathan A. Pachter, PhD; David Weaver, PhD; | Checkpoint blockade; Costimulation; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment |
| P374 | Sex-based heterogeneity of response to immunotherapy in non small cell lung cancer | Fabio Conforti, MD; Laura Pala; Vincenzo Bagnardi; Giuseppe Viale; Tommaso De Pas, MD; Elisabetta Pennacchioli; Emilia Cocorocchio; Pier Francesco F. Ferrucci, MD; Richard Gelber; Aron Goldhirsch; | Checkpoint blockade; Chemotherapy |
| P375 | Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system | Marina Pavlidou, PhD; Janet K. Peper; Lucia Pattarini; Christian Barthels; Eva-Maria Hansbauer; Rachida Bel Aiba; Milan Blanusa; Alix Scholer-Dahirel; Maximilien Grandclaudon; Celine Grand; Jamila Elhmouzi-Younes; Matthieu Rivière; Véronique Blanc, PhD; Christine Rothe; Shane Olwill; | Antibody; Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P376 | Targeting vasoactive intestinal peptide signaling to enhance immunotherapy against solid tumors | Sruthi Ravindranathan, PhD; Rebecca A. Pankove, MS; Yiwen Li, MS; Shuhua Wang, MD; Edmund K. Waller, MD, PhD, FACP; Mohammad Y. Zaidi, MD, MS; Gregory B. Lesinski, PhD, MPH; | Coinhibition; Solid tumors |
| P377 | Combination immunotherapy anti-PD-1 anti-body (Ab) with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET | Mamatha Reddy; Gavin Choy, PharmD; Sarath Kanekal, PhD; Sanjeev Redkar, PhD; | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; T cell; Targeted therapy; Tumor microenvironment |
| P378 | NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS; Saul Kivimäe; Deborah Charych, PhD; Werner Rubas, PhD; Jonathan Zalevsky, PhD; William L. Redmond, PhD | Monocyte/Macrophage; Radiotherapy; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P379 | Nanobodies® as a platform for multispecific targeting of immunomodulatory receptors. | Anandi Sawant, Ph.D.; Douglas Linn, PhD | Biomarkers; Checkpoint blockade; Gene expression; Tumor infiltrating lymphocytes (TILs) |
| P380 | Treatment-free survival (TFS), with and without immunomodulatory medications (IMMs), as a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma | Samantha Sawh; Meredith Regan, PhD; Lillian Werner; Ahmad A. Tarhini, MD, PhD; Sumati Rao, PhD; Komal Gupte-Singh, PhD; Corey Ritchings, PharmD; Michael B. Atkins, MD; David F. McDermott, MD | Checkpoint blockade; Clinical study; Solid tumors |
| P381 | Schweinfurthin natural products promote immune-dependent regression of murine melanoma and improve anti-PD-1-based immunotherapy to achieve durable complete responses and protective immunity | Kathleen Kokolus, MS, PhD; Jeremy S. Haley, MS; Emily J. Koubek; Raghavendra Gowda, PhD; Saketh S. Dinavahi, PhD; Arati Sharma, PhD; David F. Claxton, MD; Klaus F. Helm, MD; Joseph J. Drabick, MD; Gavin P. Robertson, PhD; Jeffrey D. Neighbors, PhD; Raymond J. Hohl, MD; Todd D. Schell, PhD | Checkpoint blockade; Myeloid cells; Metabolism; T cell; Tumor microenvironment |
| P382 | CD28-negative memory tumor infiltrating lymphocytes (TILs) maintain an activated cytotoxic phenotype | Lillian Seu, PhD; Bijal Kakrecha, BS; Paul Fischer, MSc; Malinda Aitken; Alice Tang; Steven Nadler, PhD; Laurence Menard, PhD; | Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P383 | Combination therapy with M7824 (MSB0011359C) and NHS-muIL12 enhances antitumor efficacy in preclinical cancer models | Chunxiao Xu, PhD; Bo Marelli; Jin Qi; Guozhong Qin; Huakui Yu; Molly H. Jenkins; Kin-Ming Lo; Joern-Peter Halle; Yan Lan, MD | Checkpoint blockade; Cytokine; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P384 | M7824 (MSB0011359C) is an effective combination partner with standard-of-care therapies in tumor models | Yan Lan, MD; Rinat Zaynagetdinov, M.D., PhD; Kenneth W. Hance; Chia Lin Chu, PhD; Chunxiao Xu, PhD; Bo Marelli; Jin Qi; Guozhong Qin; Huakui Yu; Giorgio Kradjian; Yanping Zhang; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo | Checkpoint blockade; Chemotherapy; Radiotherapy; Targeted therapy |
| P385 | Preliminary biomarker analysis of sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor | Vanessa Tassell; James Christensen; Peter Olson; Igor Rybkin, MD, PhD; Ticiana A. Leal, MD; Alexander I. Spira, MD, PhD, FACP; Collin Blakely, MD; Manish R. Patel, DO; Leora Horn, MD; Kai He, MD, PhD; David Berz, MD; Ryan Ramaekers, MD; Alison Savage; Timothy Larson; Donald Richards; Tammy Roque; Anthony Pham; Massarelli Erminia; James Uyeki; Abhinav B. Chandra, MD, FACP; Robert Jotte; Wangjian Zhong, MD; David Hong, MD; Joshua M. Lang, MD MS; Jennifer Schehr; Ticiana A. Leal, MD; Julio Fernandez Banet; Adam Pavlicek; Kai He, MD, PhD; | Biomarkers; Checkpoint blockade; Immune suppression; T cell; Targeted therapy |
| P386 | CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination | Ugur Eskiocak, PhD; Wilson Guzman, BS; Robert Tighe, BS | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion |
| P387 | A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002) | Christian Mueller, MSc; Frederic Triebel, MD, PhD; Chrystelle Brignone, PhD; Tatsiana Skrahina; Martin Forster; | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
| P388 | Combination of the Wee1 inhibitor adavosertib (AZD1775) with anti-PD-L1 shows activity in pre-clinical studies | Viia Valge-Archer, PhD; Matthew King, PhD; Chrysiis Michaloglou, PhD; Jennifer Hare; Anisha Solanki, PhD; Susan Critchlow, PhD; | Checkpoint blockade; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P389 | Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab | Trieu My T. Van, PhD; Lisette EA. Rozeman, MD; Sarah Warren, PhD; Joseph M. Beechem, PhD; John Haanen, MD PhD; Christian Blank, MD PhD; | Antibody; Biomarkers; Carcinogenesis; Checkpoint blockade; Clinical study; Clinical trial; Proteomics; Radiotherapy; Tumor microenvironment |
| P390 | Vasoactive Intestinal Peptide Antagonist Synergizing with PD1 Antibody Inhibits the Tumor Growth of Breast Cancer. | Shuhua Wang, MD; Sruthi Ravindranathan, PhD; Yiwen Li, MS; Rebecca A. Pankove, MS; Parvin Forghani; Edmund K. Waller, MD, PhD, FACP; Shuhua Wang, MD; | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Dendritic cell; Immune suppression; Inflammation; MDSC; Solid tumors; T cell; Tumor microenvironment |
| P391 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with advanced melanoma | Matthew Taylor, MD; Nicholas J. Vogelzang, MD; Allen L. Cohn; Daniel E. Stepan; Robert C. Shumaker, Ph.D.,; Corina E. Dutcus; Matthew Guo; Emmett Schmidt, MD PhD; Drew Rasco; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P392 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer | Marcia S. Brose, MD PhD; Nicholas J. Vogelzang, MD; Christopher Di Simone; Sharad K. Jain, MD; Donald Richards; Carlos A. Encarnacion; Drew Rasco; Robert C. Shumaker, Ph.D.,; Corina E. Dutcus; Daniel E. Stepan; Matthew Guo; Emmett Schmidt, MD PhD; Matthew Taylor, MD; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P393 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with urothelial cancer | Nicholas J. Vogelzang, MD; Carlos A. Encarnacion; Allen L. Cohn; Christopher Di Simone; Drew Rasco; Donald Richards; Matthew Taylor, MD; Corina E. Dutcus; Daniel E. Stepan; Robert C. Shumaker, Ph.D.,; Matthew Guo; Emmett Schmidt, MD PhD; James W. Mier, MD; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P394 | CX3CR1+CD8+ T cells is responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade | Yiyi Yan, MD PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Haidong Dong, MD, PhD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; T cell |
| P395 | PD-1 blockade synergies with RetroNectin-activated cytokine-induced killer cells in pretreated metastatic renal cell cancer | Lingdi Zhao; Yonghao Yang; Tiepeng Li; Yong Zhang; Wei Li; Lu Han; Hongwei Lin; Quanli Gao | Adoptive immunotherapy; Checkpoint blockade |
| P396 | Phase I trial of interferon-gamma (IFN-g) combined with nivolumab (nivo) in patients with advanced solid tumors | Matthew Zibelman, MD; Alexander W. Macfarlane; Kimberly Costello; Thomas McGowan; John P. O'Neill, BA; Rutika Kokate; Igor Astsaturov; Matthew Zibelman, MD; Matthew Zibelman, MD; Hossein Borghaei, MS, DO; Christina Chu, MD; Crystal Denlinger; Efrat Dotan, MD; Daniel Geynisman; Angela Jain, MD; Lainie Martin, MD; Elias Obeid, MD, MPH; Joseph Treat, MD; Namrata Vijayvergia, MD; Rohit Walia; Jennifer S. Winn, MD, MS; Jeffery A. Nieves, PharmD; Amy Grahn, MS; Jeffrey W. Sherman, MD, FACP; Karthik Devarajan; Karen Ruth; R K. Alpaugh, PhD; Essel D. Al-Saleem; Edna Cukierman, PhD; Kerry S. Campbell, PhD; Elizabeth R. Plimack, MD MS; | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors |
| O24 | A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors | Charu Aggarwal, MD MPH; Anthony Joshua, MD; Robert L. Ferris, MD, PhD; Scott J. Antonia, MD, PhD; E E. Rahma, MD; Anthony W. Tolcher, MD, FRCP(C); Roger Cohen; Yanyan Lou, MD; Ralph J. Hauke, MD; Nicholas J. Vogelzang, MD; Dan Zandberg, MD; Arash Rezazadeh Kalebasty, MD; Victoria Atkinson, MD; Alex A. Adjei, MD PhD; Mahesh Seetharam; Ariel Birnbaum, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Vinod Ganju, MBBS, FRACP; Riva Bondarenko, PhD; Linda Peng, MS; Tony Wu, PhD; Scott Currence; Jan Baughman, MPH; Ezio Bonvini; Stacie Goldberg, MD; Jon M. Wigginton, MD; Nehal Lakhani, MD, PhD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| O25 | Phase 1 dose-finding study of the anti–TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Talia Golan; Todd M. Bauer, MD; Antonio Jimeno, MD, PhD; Ruth Perets; Jiaxin Niu; James J. Lee, MD, PhD; Mallika Lala; Jennifer Garrus; Zhen Zeng; Elliot Chartash; Jane Healy; Drew Rasco, MD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| O26 | The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study | Nehal Lakhani, MD, PhD; Todd M. Bauer, MD; Anson K. Abraham, PhD; John Luddy; John Palcza, MS; Elliot Chartash; Jane Healy; Amita Patnaik, MD FRCP© | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| O27 | Phase 2 trial of mocetinostat in combination with durvalumab in NSCLC patients with progression on prior checkpoint inhibitor therapy | Melissa L. Johnson, MD; Keith Eaton, MD; Supporting Author - Balazs Halmos, MD; Supporting Author - Edward B. Garon, MD; Supporting Author - Thomas Hensing, MD; Supporting Author - Nisha A. Mohindra, MD; Supporting Author - James Strauss, MD; Supporting Author - Timothy McCarthy; Supporting Author - Rami Owera; Supporting Author - Isan Chen, MD; Supporting Author - Peter Olson; Supporting Author - Demiana Faltaos, PharmD, PhD; Supporting Author - James Christensen; Supporting Author - Diane Potvin; Supporting Author - Tavette Neskorik; Supporting Author - Adam Pavlicek; Presenting Author - Manish R. Patel, DO; Primary Author - Manish R. Patel, DO; | Checkpoint blockade; Clinical trial; Tumor microenvironment |
| O28 | Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma | Frederic Triebel, MD, PhD; Christian Mueller; Chrystelle Brignone; Victoria Atkinson, MD; Melissa Eastgate, MD; Amitesh Roy, MD; Adnan Khattak, MD; Andrew Haydon, MBBS PhD | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
